Studies carried out in partnership with the United States, at the height of the health crisis in Manaus, pointed to a possible decrease in mortality and hospitalization days with the use of proxalutamide
The president Jair Bolsonaro invited to the live of this Thursday, 8, the national secretary of Science, Technology, Innovation and Strategic Inputs of the Ministry of Health, Helio Angotti, who spoke about proxalutamide, a drug that would have been developed in Manaus by Brazilian and American researchers to assist in the treatment of patients with Covid-19. “The vaccine is something to prevent. After contracting the virus, you have to look for medicine, ”said the president. According to the secretary, the drug was researched in one of the most serious moments of the Covid-19 crisis in Manaus and proved to be promising. “The results show that, in critically ill patients, it reduced the chance of mortality from 47.6% to 3.7%. This was announced by the researchers there. This represents a 92% drop in mortality and also reduced the number of days of hospitalization, which dropped from 14 to five days. This all fits in with that effort, which is integral, comprehensive care for those who have Covid, ”he said.
According to Angotti, who cited that the data had been released recently, the government is waiting for the publication of the results of the research carried out in Manaus; there is another study currently in phase 3 in the United States and the National Research and Ethics Commission of Brazil evaluates the possibility of new research in Brazil. “There we have an initiative by Fiocruz to take material to Anvisa and submit the data, including thinking about an expanded research in phase 3, within Anvisa’s strict parameters, with all its technical excellence, even to obtain an emergency authorization. Our objective is, proving all this benefit, to give access to the Brazilian population as soon as possible ”, he said. Questioned by presenter Vitor Brown, from the program “Pingos nos Is ”, on the progress of procedures in Brazil for the legalization of nasal spray developed in Israel against serious forms of the disease, the secretary recalled that it is still in the first phase of research and needs to be tested on a larger scale of patients.
Angotti said that national dealings with the Ministry of Science and Technology and Innovations are made so that, if Israel’s studies show effective results, another one can be conducted in Brazilian patients. “Especially in slightly more severe states, in patients who need oxygen. We are following the development of these researches, they were going to enter phase 2 and the negotiations were very centralized there too, together with the Ministry of Science, Technology and Innovation ”, he said. Brazil broke another record of deaths per day caused by Covid-19 this Thursday, with 4,249 deaths. So far, according to data from the National Council of State Health Secretaries (Conass), the total number of deaths from the disease is 345,025 and more than 13 million people have been infected since the beginning of the pandemic.